Prime Medicine, Inc. (PRME)
NASDAQ · Healthcare
$3.05-2.56%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $682.73M
- P/E ratio
- —
- EPS
- —
- Volume
- 3,273,878
- 52-week high
- —
- 52-week low
- —
- Open
- $3.14
- Day high
- $3.22
- Day low
- $3.03
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $4.63M | -$201.14M | -$1.35 |
| 2024 | $2.98M | -$195.88M | -$1.65 |
| 2023 | $0 | -$198.13M | -$2.18 |
| 2022 | $0 | -$121.82M | -$4.19 |
| 2021 | $0 | -$165.37M | -$14.19 |
About Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
- CEO
- Allan Reine
- Employees
- 146
- Country
- US
- IPO date
- Oct 20, 2022
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Prime Medicine, Inc.'s stock price today?
- PRME is trading at $3.05 as of Jul 20, 2026.
- What is Prime Medicine, Inc.'s market cap?
- Prime Medicine, Inc. (PRME) has a market capitalization of $682.73M.
- Does Prime Medicine, Inc. pay a dividend?
- Prime Medicine, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Prime Medicine, Inc. in?
- Prime Medicine, Inc. operates in the Healthcare sector.